When siP53-transfected cells were subsequently treated with cisplatin for 48 hours, the proportion of sub-G0/G1 cells increased to 51.51%, suggesting that the p53-targeting siRNA can co-operate with cisplatin in the inhibition of bladder cancer cells. Here, TP53 is linked to urinary bladder carcinoma.